US Food and Drug Administration has given its clearance to the Cadila Healthcare's facilities at Moraiya after it had issued a warning letter in June 2011 over non-conformity of norms.

The company informed the stock exchanges n filing that the warning letter has been revoked by the US FDA. The US watchdog had issued the warning letter it was concerned that the non-conformity with its laws would mean that the company's could be adulterated.

Cadila is an innovative global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare products. The group’s operations range from API to formulations, animal health products and cosmeceuticals. Headquartered in the city of Ahmedabad in India, the group has global operations in four continents spread across USA, Europe, Japan, Brazil, South Africa and 25 other emerging markets. In its mission to create healthier communities globally, Zydus Cadila delivers wide ranging healthcare solutions and value to its customers.

Technical analyst Anil Singhvi has maintained 'buy' rating on Cadila Healthcare Limited stock with an intra-day target of Rs 820.

According to analyst, the investors can purchase the stock with a stop loss of Rs 761.

The stock of the company, on January 17, closed at Rs 774.90 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 809.45 and a low of Rs 422.94 on BSE.

Current EPS & P/E ratio stood at 30.72 and 25.81 respectively.

Technical analyst Hitesh Chotalia has maintained 'buy' rating on Cadila Healthcare Limited stock with a short term target of Rs 800.

According to analyst, the investors can purchase the stock with a stop loss of Rs 760.

The stock of the company, on December 14, closed at Rs 774.20 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 809.45 and a low of Rs 421.54 on BSE.

Current EPS & P/E ratio stood at 30.72 and 25.30 respectively.

At 11:04 IST on BSE, Cadila Healthcare put on 1.17% to Rs. 697.10, subsequent to the company rolled out the Pramipexole tablets in manifold power in the United States. The group made this declaration, today in the trading hours, 14 October 2010.

In the meantime, the BSE Sensex was moving up by or 0.07% at 20702.69 or 14.81 points. On BSE, 5,366 equities were dealt in counteract as adjacent to a standard daily amount of 29,452 shares in the precedent one quarter.

Cadila Healthcare Limited is one of the largest Indian companies in the domestic pharmaceutical market. The company is the flagship of the Zydus Cadila group. Its operations include pharmaceuticals, diagnostics, herbal products, skin care products and other over-the-counter products. Company came into current status after the group restructuring in 1995 under which the operations of the group were consolidated. The company also has co-marketing agreement with number of Indian drug companies like E. Merck, Kopran, Nicholas Piramal and Ranbaxy.

Cadila Healthcare has informed that it has posted a 60% hike in its net profit figure. It has announced its financial results for the June quarter of the fiscal year 2010-11.

According to the company, it has registered a net profit of Rs 199.18 crore for the quarter that ended in 30th June, 2010. Last year, the company had registered a net profit of Rs 124.79 crore in the corresponding quarter.

Cadila Healthcare, the parent company of the Zydus Cadila group, has finally secured approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Topiramate capsules.

Topiramate drug is indicated as an initial monotherapy in patients 10 years old or older with partial onset or primary generalized tonic-clonic seizures.

In addition, the drug is also indicated as an adjunctive therapy for adults and pediatric patients aged 2 - 16 with partial onset seizures, or primary generalized tonic-clonic seizures, and in patients 2 years of age or older with seizures associated with Lennox-Gastaut syndrome.

The Rs 3000-crore Zydus Group's listed entity Cadila Healthcare has finally secured nod from US FDA for Topiramate capsules in multiple strengths.

The drug, which is the generic version of Ortho McNeil's Topamax capsules, is indicated as initial monotherapy in patients 10 years of age and older with partial onset or primary generalized tonic-clonic seizures.

Topiramate Tablets are available as 25 mg, 50 mg, 100 mg, and 200 mg round tablets for oral administration. The drug had total sale of $58 million in US market for the 12 month ended June 2009.

Cadila Healthcare Limited is one of the largest Indian companies in the domestic pharmaceutical market. The company is the flagship of the Zydus Cadila group. Its operations include pharmaceuticals, diagnostics, herbal products, skin care products and other over-the-counter products. Company came into being after the group restructuring in 1995 under which the operations of the group were consolidated. The company also has co-marketing agreement with number of Indian drug companies like E. Merck, Kopran, Nicholas Piramal and Ranbaxy.